Debt reduction on the right trajectory
14/03/25 -"Reflecting similar reasoning from the FY23/24 actual figures, we have increased our financial expense estimates for the next two fiscal years, keeping our operating profit forecasts unchanged. We ..."
Pages
50
Language
English
Published on
14/03/25
You may also be interested by these reports :
08/05/25
Qiagen commenced 2025 positively, with robust performance in Diagnostic Solutions and PCR/Nucleic Acid Amplification, although this was partially ...
08/05/25
Demant’s Q1 results met market expectations. Growth in Hearing Care was counterbalanced by weakness in Hearing Aids. Meanwhile, Diagnostics remained ...
07/05/25
DiaSorin’s Q1 results marginally surpassed market expectations, demonstrating good performance across all segments. Profitability improved and ...
07/05/25
Q2 figures exceeded expectations, surpassing consensus estimates (sales: +2.0%; adjusted EBIT: +4.4%). This was primarily due to pre-buying ...